Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA’s 75% Growth in U.S. Prostacyclin Revenue

With important upside potential, Liquidia Corporation (NASDAQ:LQDA) secures a spot connected our database of the best small-cap biotech stocks to bargain according to analysts.

On November 4, 2025, Raymond James raised its terms people connected Liquidia Corporation (NASDAQ:LQDA) from $41 to $47, portion reiterating a “Strong Buy” rating. The concern firm’s bullish stance reflects YUTREPIA’s 75% maturation successful U.S. prostacyclin gross during the 3rd quarter, which turned profitable earlier than expected. Meanwhile, the institution raised highest income estimates to $2 cardinal from $1.1 billion, acknowledgment to beardown aboriginal motorboat performance. The raised guidance boosted expert sentiment.

Liquidia Corporation (NASDAQ:LQDA) announced Q3 2025 results connected November 3, 2025, reporting YUTREPIA nett income of $51.7 million. The 4th marked a nett nonaccomplishment of $3.5 million, oregon $0.04 per diluted share, and affirmative adjusted EBITDA of $10.1 million. However, YUTREPIA achieved profitability successful the archetypal 4th of its afloat commercialized launch. Over 1,500 patients were enrolled successful the therapy, alongside much than 2,000 prescriptions, and beardown payer sum was achieved done contracts with the 3 largest commercialized payers.

Liquidia Corporation (NASDAQ:LQDA) ended the 4th with $157.5 cardinal successful currency connected hand, reporting a nett currency travel of $5 cardinal successful September. The company’s short-term gross designation was affected contempt beardown aboriginal commercialized uptake, arsenic astir 50% of caller patients utilized a 28-day voucher program. Meanwhile, Liquidia is looking for further objective applications successful IPF and PPF.

With its proprietary PRINT and TRIA platforms, Liquidia Corporation (NASDAQ:LQDA), a clinical-stage pharmaceutical company, focuses connected processing therapies for pulmonary arterial hypertension and related cardiopulmonary diseases.

While we admit the imaginable of LQDA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.